We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Vertex Pharmaceuticals Inc | NASDAQ:VRTX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.40 | -0.61% | 391.08 | 390.00 | 394.24 | 396.98 | 391.25 | 394.72 | 1,342,139 | 01:00:00 |
From Apr 2019 to Apr 2024
By Micah Maidenberg
Vertex Pharmaceuticals Inc. said U.S. regulators will allow three of its cystic fibrosis medicines to treat more patients.
Vertex on Monday said the expanded availability for the three therapies will allow more than 600 people with certain rare cystic fibrosis mutations to potentially access its drugs Trikafta, Symdeko or Kalydeco.
Write to Micah Maidenberg at micah.maidenberg@wsj.com
(END) Dow Jones Newswires
December 21, 2020 15:14 ET (20:14 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Vertex Pharmaceuticals Chart |
1 Month Vertex Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
